Full Text View
Tabular View
Study Results
Related Studies
Prophylactic Efficacy of Relenza Against Influenza A and B
This study has been completed.
Study NCT01156701   Information provided by GlaxoSmithKline

First Received on April 22, 2010.   Last Updated on June 2, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Bronchospasm
Influenza, Human
Asthma
Respiratory Disease
Exacerbation of COPD
Bronchitis
Otitis Maedia
Pneumonia
Sinusitis
Additional conditions recognized in this trial
Bronchial Spasm
Chronic Disease
Lung Diseases
Otitis
Pulmonary Disease, Chronic Obstructive
Respiration Disorders
Respiratory Tract Diseases
More general conditions related to this trial
Bronchial Diseases
Disease Attributes
Ear Diseases
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Lung Diseases, Obstructive
Nose Diseases
Orthomyxoviridae Infections
Otorhinolaryngologic Diseases
Paranasal Sinus Diseases
Pathologic Processes
Respiratory Hypersensitivity
Respiratory Tract Infections
RNA Virus Infections
Virus Diseases
Interventions listed in this trial
No prophylaxis with Relenza
Additional drug interventions recognized in this trial
Zanamivir
More general drug interventions related to this trial
Anti-Infective Agents
Antiviral Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
GlaxoSmithKline


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services